4//SEC Filing
Niklason Laura E 4
Accession 0001628280-25-052715
CIK 0001818382other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 5:48 PM ET
Size
5.6 KB
Accession
0001628280-25-052715
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Niklason Laura E
DirectorPresident, CEO and Director
Transactions
- Award
Stock Options (right to buy)
2025-11-16+311,100→ 311,100 totalExercise: $1.23Exp: 2035-11-16→ Common Stock (311,100 underlying)
Footnotes (1)
- [F1]The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001878075
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 5:48 PM ET
- Size
- 5.6 KB